 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Background Academic research in the medical field is of no value unless it is developed into applications that can improve health. To meet this need Karolinska Institutet took the initiative to establish Karolinska Institutet Innovations AB (KIAB), part of KI Innovation System. We at Karolinska Development now enable innovations coming out of Nordic academic and research institutions to be developed in to products that deliver benefits to human health, and give the best possible financial return for all parties involved in their development. We have our roots in the venture capital companies Karolinska Development I and Karolinska Development II, which were formed in 2003 and 2005 respectively to secure seed financing for the many innovations coming from researchers at the Karolinska Institute. Over a short period of time they demonstrated the ability to advance life science innovations towards commercially viable products at a competitive pace using a highly cost effective approach. We are now a substantial investor in several of the life science companies with products in different development stages, that had their initial financing from Karolinska Development l and Karolinska Development ll. In contrast to the previous venture capital companies, Karolinska Development provides evergreen investment affording more flexibility to grow business opportunities to achieve the optimum exit point, for both owners and innovators. About half of all innovations come from KIAB which is a life science incubator specializing in early stage support, creating startup companies based on academic inventions . KIAB annually reviews a significant number of inventions and innovative ideas from a large number of leading Nordic academic institutions. Karolinska Institutet is one of the leading medical universities in the world with more than 2000 researchers publishing about 4000 reviewed scientific papers annually. Through an exclusive agreement we have the right of first refusal to all innovations from KIAB, enabling us to invest in the best commercial start up opportunities that are reviewed by KIAB. Click on the icons to download a pdf of the material below:
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
